

S.N. 09/809,173
Group Art Unit 1615

Amendment A

EXHIBIT B

CLEAN SET OF ALL PENDING CLAIMS

FOLLOWING ENTRY OF THE PRESENT AMENDMENT

424/489

1. A process of making a solid pharmaceutical composition comprising moexipril magnesium, said process comprising the step of reacting moexipril or an acid addition salt thereof with an alkaline magnesium compound in the presence of a solvent so as to convert most or all of the moexipril or moexipril acid addition salt to moexipril magnesium.
2. The process of Claim 1 comprising the steps of:
 - i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent and mixing in the liquid state;
 - ii) evaporating the solvent to obtain a dried material, and
 - iii) further processing the dried material into the solid pharmaceutical composition.
3. The process of Claim 2 wherein, before the solvent is evaporated, the liquid is filtered to remove unreacted alkaline magnesium compound.
4. The process of Claim 2 or 3 wherein the solvent is evaporated by spray-drying.

5. The process of Claim 1 comprising the steps of:
 - i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent;
 - ii) using the resultant solution or suspension to wet granulate other excipients to obtain a wet mass;
 - iii) drying the wet mass to obtain a dried mass; and
 - iv) further processing the dried mass into the solid pharmaceutical composition.
6. The process of Claim 1 comprising the steps of:
 - i) adding the alkaline magnesium compound to solvent;
 - ii) using the resulting solution or suspension to wet granulate a mixture of the moexipril or acid addition salt thereof and one or more excipients to obtain a wet mass;
 - iii) drying the wet mass to obtain a dried mass; and
 - iv) further processing the dried mass into the solid pharmaceutical composition.
7. The process of Claim 1 comprising the steps of:
 - i) adding the moexipril or acid addition salt thereof to solvent;
 - ii) using the resultant solution or suspension to wet granulate a mixture of the alkaline magnesium compound and one or more other excipients to obtain wet mass;

- iii) drying the wet mass to obtain a dried mass, and
 - iv) further processing the dried mass into the solid pharmaceutical composition.
8. The process of Claim 1 comprising the steps of:
- i) mixing the moexipril or acid addition salt thereof and alkaline magnesium compound with one or more other excipients;
 - ii) adding a solvent and mixing to obtain a wet mass;
 - iii) drying the wet mass to obtain a dry mass; and
 - iv) further processing the dried mass into the solid pharmaceutical composition.
9. The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.
10. The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.
11. The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

12. The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.

13. The process of Claim 12 wherein the percentage of the moexipril or acid addition salt thereof converted to moexipril magnesium is substantially greater than 90%.

14. A solid pharmaceutical composition comprising moexipril magnesium.

15. The process of Claim 4 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

16. The process of Claim 4 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

17. The process of Claim 4 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

18. The process of Claim 4 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.